Latent Tuberculosis Infection in Korean Health Care Workers

NCT ID: NCT03010111

Last Updated: 2017-01-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to study the prevalence of latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays, and determine the risk factors of LTBI in Korean health care workers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Further study details as provided by Hanyang University Hospital

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Latent Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

health care workers

health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital

Group Type OTHER

QFT-IT Test and other blood sampling

Intervention Type OTHER

In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QFT-IT Test and other blood sampling

In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Health care workers in University affiliated hospital
* Adult aged 20-65

Exclusion Criteria

* Active tuberculosis
* Subjects diagnosed with HIV infection, malignancy
* Subjects having immunosuppressive drug therapy
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hanyang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dong Won Park

assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jang Won Shon, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Hanyang University Hospital, Seoul, Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hanyang University Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dong Won Park, M.D., Ph.D.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jang Won Shon, M.D., Ph.D.

Role: primary

82-2-2290-8351

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HYUMC_CM_001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.